News

31 May 2022

ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure

27 May 2022

MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval

23 May 2022

DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology

23 May 2022

FDA Lifts Clinical Hold on Long-Acting Lenacapavir

1 April 2022

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain

1 April 2022

Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevent

1 April 2022

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Re

4 March 2022

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

28 February 2022

Europe Accelerates Long-acting RSV Antibody Assessment in Infants

28 February 2022

Long-acting HIV-1 Capsid Inhibitor Sustained Efficacy in Phase 2/3 Study

28 February 2022

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV

28 February 2022

Pfizer gets EU approval for long-acting human growth hormone, softening blow of FDA rejection

14 February 2022

ViiV Healthcare Long-acting HIV treatment secures FDA approval

6 February 2022

Long-acting injectable for HIV prevention 'overpriced'

6 February 2022

GlaxoSmithKline's HIV drug Cabenuva scores FDA nod for 2-month dosing

6 February 2022

Injectables for schizophrenia reduce hospitalisations better than oral medications, study shows

6 February 2022

HIV Prevention, Treatment: Playing the Long Game

24 January 2022

New Injectable HIV Prevention Drug Approved By FDA

14 January 2022

Implementing Injectables

20 December 2021

National Institute of Health and Care Excellence has signed off on offering pre-exposure prophylaxis treatment to people at a high risk of contracting HIV